The G5 Health Association presents its 20 proposals for 2017: Choice of France as a leading country for healthcare industries

Publié le 11 octobre 2016

boutonParis, October 10, 2016 – At its 5th Meetings, the G5 Health Association presented its 2017-2022 white paper entitled “Making France a leading country for healthcare industries: reforming, investing and innovating to benefit patients.”

 

Based on the overarching theme “Are healthcare industries strategic for France? Which reforms are needed?” and four round tables, this fifth day of the G5 Health Association event served as an opportunity to discuss the forum’s proposals with a wide range of stakeholders.

 

Healthcare is a key business sector for France. Companies in the sector have considerable economic clout muscle given that they generate jobs and investment across the entire country and export throughout the world. Their technology-intensive expertise, capacity for innovation and excellence in research and engineering give France a sustainable competitive advantage. Moreover, healthcare companies are important to foster the independence of our medical system and provide social added value through complementary business lines and their wide range of products. This means better patient management and a more efficient healthcare system.

 

For all that, the pressures in the healthcare market in general have intensified in recent years. The environment this fall is of particular concern: dialog with public authorities is increasingly difficult, as shown by the signature of a guidance letter this summer to the Chairperson Chairman of France’s Comité Economique des Produits de Santé (CEPS), including numerous provisions that challenge the framework agreement signed between the CEPS and Les Entreprises du médicament (LEEM – French pharmaceutical trade association) in January 2016.

Owing to the lack of structural reform, half of the savings needed to ensure the long-term sustainability of the French healthcare system will come from the industry itself, irrespective of industrial, social, scientific, medical and strategic considerations. France’s “PLFSS 2017” draft bill for financing the social security system is a perfect illustration of this situation, where healthcare industries have been asked to make a cost-cutting effort of almost
€2 billion.

 

 

In the words of Marc de Garidel, Chairman of the G5 Health Association and Vice President of France’s Healthcare Industries and Technologies Strategic Committee: “G5 Health is a think tank that aims to offer constructive proposals and suggestions for reform to improve the efficiency of the healthcare system during a period innovation in medical technology is being stepped up.

 

This white paper and the proceedings of these 5th Meetings are intended to promote awareness of the importance and urgency of establishing an Alliance over the next five years between public authorities and the healthcare industry in France to ensure optimum care for patients while safeguarding the competitiveness of healthcare businesses.« 

 

G5 Health seeks to raise awareness of the need to act differently, and suggests 20 measures to start constructive dialog ahead of France’s 2017 electoral platforms, including the following in particular:

 

  • Determining responsible prices for healthcare products: evaluation and pricing must factor in all the consequences of therapeutic innovations, especially their impact on the organization of the actual care, the efficiency provided to the healthcare system, and potential savings generated across the entire treatment chain.
  • Developing a face value policy pricing for drugs widely exported from France to safeguard industrial sites at no extra cost to health insurance, based on the payment of export credit’s rebates.
  • Fully applying the framework agreement: take account of investments made in France and in the European Union when setting drug prices and reviewing price conditions. Externalities such as research, development, production and job creation must be given real consideration in the conditions for putting—and maintaining—a healthcare product on the market, in terms of both price and lead times. This is a key issue both for France’s attractiveness and for the competitiveness of its businesses.
  • Improving the efficiency of the healthcare system by considering the organizational consequences of breakthrough innovations that modify patient care: improve utilization of diagnostic testing, adjust care pathways, and develop outpatient care and day surgery.
  • Strengthening dialog and promoting partnerships between the public and private sectors in medical research, in particular by drawing on France’s Alliance pour la Recherche et l’Innovation des Industries de Santé (ARIIS – French Alliance for Research and Innovation in Health Industries) and its Alliance nationale pour les sciences de la vie et de la santé (AVIESAN – French National Alliance for Life Sciences and Health), and launching a national innovation plan, notably to develop advanced therapy medicinal products (ATMPs).
  • Building an Alliance between public authorities and the healthcare industry in France for the next five years to improve France’s competitiveness, raise its profile in Europe’s public health policy, and increase its presence in European and global calls for projects.

 

We are on the crest of an unprecedented wave of medical innovation, one that carries with it real hope for many patients. We can secure the necessary financing and ensure the benefits are available to everybody, provided we adopt a global, long-term vision of healthcare system regulation to manage change and breakdown organizational barriers in the system. Many of the obstacles observed prevent us from getting the most out of the efficiency gains delivered by a number of new products for the benefit of patients and the healthcare system alike.

 

 

 

About the G5 Health Association (http://www.g5.asso.fr)

 

 

The G5 Health Association, the voice of the French healthcare industry, is a forum for the leaders of the major health and bio-science companies in France (bioMérieux, Guerbet, Ipsen, Laboratories Théa, LFB, Pierre Fabre, Sanofi, Servier), presided over by Marc de Garidel, Non-Executive Chairman of Ipsen. These companies have chosen France as the base for their international development, and make R&D their priority.

The members of the G5 Health Association share five ambitions: gaining recognition for the crucial contribution of life sciences to public health in France; helping to restore France’s competitive position; pursuing excellence in French bio-medical research; improving patients’ access to health solutions; supporting the biotechnology and new technology sector.

In 2015, the member companies of the G5 Health Association had sales of more than €47 billion throughout the world, employed 165,000 people, and earmarked more than €6.7 billion to R&D, half of which in France.

They employ more than 47,000 people across France, more than 20,000 of whom work in production, and invest nearly €700 million. With a contribution of almost €9 billion to the trade balance surplus, the G5 Health Association plays a key role in France’s economy.

 

 

 

Press Contact

Didier Véron – Tel.: +33 (0)1 58 33 51 16 Email: g5@g5.asso.fr

Revenir à la liste des articles
contact -plan de site - mentions légales

copyright 2011 G5